Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok
Journal of Clinical Oncology (2015) Vol. 33, Iss. 17, pp. 1974-1982
Open Access | Times Cited: 2435

Showing 1-25 of 2435 citing articles:

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al.
Breast Care (2016) Vol. 11, Iss. 6, pp. 385-390
Open Access | Times Cited: 30388
Cancer immunotherapy using checkpoint blockade
Antoni Ribas, Jedd D. Wolchok
Science (2018) Vol. 359, Iss. 6382, pp. 1350-1355
Open Access | Times Cited: 5337
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero, Laura Kulik, Claude B. Sirlin, et al.
Hepatology (2018) Vol. 68, Iss. 2, pp. 723-750
Open Access | Times Cited: 3865
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 20, pp. 1919-1929
Open Access | Times Cited: 3826
Determining cell type abundance and expression from bulk tissues with digital cytometry
Aaron M. Newman, Chloé B. Steen, Chih Long Liu, et al.
Nature Biotechnology (2019) Vol. 37, Iss. 7, pp. 773-782
Open Access | Times Cited: 3311
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, et al.
The Lancet (2016) Vol. 389, Iss. 10066, pp. 299-311
Open Access | Times Cited: 2871
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma, James P. Allison
Cell (2015) Vol. 161, Iss. 2, pp. 205-214
Open Access | Times Cited: 2092
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2036
Chimeric Antigen Receptor Therapy
Carl H. June, Michel Sadelain
New England Journal of Medicine (2018) Vol. 379, Iss. 1, pp. 64-73
Open Access | Times Cited: 1850
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab, Samaresh Sau, Rami M. Alzhrani, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 1521
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Cell (2017) Vol. 170, Iss. 6, pp. 1109-1119.e10
Open Access | Times Cited: 1309
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 11, pp. 1480-1492
Closed Access | Times Cited: 1227
Tumor microenvironment as a therapeutic target in cancer
Yi Xiao, Dihua Yu
Pharmacology & Therapeutics (2020) Vol. 221, pp. 107753-107753
Open Access | Times Cited: 1226
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq, Christopher S. Hackett, Renier J. Brentjens
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 3, pp. 147-167
Open Access | Times Cited: 1123
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Nathalie Chaput, Patricia Lepage, Clélia Coutzac, et al.
Annals of Oncology (2017) Vol. 28, Iss. 6, pp. 1368-1379
Open Access | Times Cited: 1089
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia, Augusto Villanueva, Scott L. Friedman, et al.
Gastroenterology (2016) Vol. 152, Iss. 4, pp. 745-761
Open Access | Times Cited: 1003
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
Joe‐Elie Salem, Ali Manouchehri, Melissa Moey, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 12, pp. 1579-1589
Open Access | Times Cited: 964
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros, Ahmad A. Tarhini, Émilie Routier, et al.
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 8, pp. 473-486
Closed Access | Times Cited: 947
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt, Marie Vétizou, Romain Daillère, et al.
Immunity (2016) Vol. 44, Iss. 6, pp. 1255-1269
Open Access | Times Cited: 930
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Woosung Chung, Hye Hyeon Eum, Hae‐Ock Lee, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 899
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Claudio Luchini, Frédéric Bibeau, M. Ligtenberg, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1232-1243
Open Access | Times Cited: 813
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S. Gordon, Sunil Sharma, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 26, pp. 3119-3125
Open Access | Times Cited: 812
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Peter H. O’Donnell, Christophe Massard, et al.
JAMA Oncology (2017) Vol. 3, Iss. 9, pp. e172411-e172411
Open Access | Times Cited: 810
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert, et al.
Nature Reviews Clinical Oncology (2015) Vol. 13, Iss. 4, pp. 228-241
Closed Access | Times Cited: 774
The Basis of Oncoimmunology
Karolina Palucka, Lisa M. Coussens
Cell (2016) Vol. 164, Iss. 6, pp. 1233-1247
Open Access | Times Cited: 740
Page 1 - Next Page

Scroll to top